Clinical trials: Disorder, Mood
Major Depression
Low Dose St John's Wort for Depression
This observational study observes the routine use of low-dose St John's Wort herbal mother tincture in patients with major depression.
- Trial name
- NCT05477472
- Testing
- St John's Wort
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- Ceres Heilmittel AG
Major Depressive Disorder
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
This study will determine the efficacy, safety, and tolerability of a 40 milligrams (mg) once-daily (QD) dose of LY2940094 for 8 weeks in participants with MDD.
- Trial name
- NCT01724112
- Testing
- LY2940094
- Where
- 10 sites in United States
- Volunteers
- 136 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major, Major Depressive Disorder (MDD)
A Local Register Study For Major Depression Of Paroxetine Controlled Release
The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to Paroxetine Immediate Release, as well as the drug tolerability profile when treated on patients with Major Depression.
- Trial name
- NCT00368303
- Testing
- Paroxetine CR, Paroxetine IR
- Where
- 11 sites in China
- Volunteers
- 362 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Bipolar Disorder, Depression, Bipolar
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- NCT00060489
- Testing
- SEROQUEL (quetiapine fumarate) Tablets
- Where
- 27 sites in United States
- Sponsor
- AstraZeneca
Depressive Disorder and Anxiety Disorders
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).
- Trial name
- NCT00426608
- Testing
- metyrapone, alprazolam, GSK561679
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depression, Depressive Disorder
Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder
Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- ELATED-4 (NCT06934135)
- Testing
- Bilateral Near-Infrared Transcranial Photobiomodulation (tPBM)
- Where
- 2 sites in Peru
- Volunteers
- 50 people
- Sponsor
- NeuroThera DE
Pregnancy Related, Mental Health Issue
MamaConecta: Digital Tool for Maternal Mental Health
The goal of this randomized controlled trial is to validate a digital health tool, Dana app, that enhances well-being and supports mental health monitoring for women during the perinatal period.
- Conditions
- Pregnancy Related, Mental Health Issue, Postpartum Depression, Postpartum Anxiety
- Trial name
- DDT (NCT06442774)
- Testing
- Mobile application, Monitoring via wearable
- Where
- 3 sites in Spain
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- A Thousand Colibris, S.L
Treatment Resistant Depression
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
- Trial name
- CX157-201 (NCT01246908)
- Testing
- CX157 (TriRima)
- Where
- 30 sites in United States
- Volunteers
- 360 people
- Sponsor
- CeNeRx BioPharma Inc.
Major Depression
Prediction of SSRI Treatment in Major Depression.
This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment.
- Trial name
- NCT03670823
- Testing
- SIEMENS PRISMA MRI
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
The main aim of the study is to check how well vortioxetine 10 mg/day or 20 mg/day works and to check for side effects compared to a placebo on depression symptoms in Japanese teenagers aged 12 to 17 years with a diagnosis of…
- Trial name
- NCT07204314
- Testing
- Vortioxetine tablets
- Where
- 30 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Takeda
Major Depressive Disorder
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
- Trial name
- AGN-241751 (NCT03726658)
- Testing
- AGN-241751
- Where
- 5 sites in United States
- Volunteers
- 226 people
- Sponsor
- Syndeio Biosciences, Inc
Bipolar Disorder
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents.
- Trial name
- NCT00050206
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042575
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Premenstrual Syndrome, Menstrual Pain
A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms
This is a single-group, virtual clinical trial evaluating the effects of a daily dietary supplement (DITTO Cycle Supplement) on menstrual cycle symptoms across three menstrual cycles.
- Trial name
- NCT07267728
- Testing
- DITTO Cycle Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Muse Nutrition Ltd
Major Depressive Disorder (MDD)
A Study in Patients With Major Depressive Disorder
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
- Trial name
- NCT03642964
- Testing
- CTC-501
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.